

- receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. *Nature medicine* 19 (2013): 1023-1029.
13. Vara JÁF, et al. PI3K/Akt signalling pathway and cancer. *Cancer treatment reviews* 30 (2004): 193-204.
 14. Centelles JJ. General Aspects of Colorectal Cancer. *ISRN Oncology* (2012) 2012.
 15. Crumbaker M, L Khoja, AM Joshua. AR signaling and the PI3K pathway in prostate cancer. *Cancers* 9 (2017): 34.
 16. MacDonald BT, K Tamai, X He. Wnt/ β -catenin signaling: components, mechanisms, and diseases. *Developmental cell* 17 (2009): 9-26.
 17. Morin PJ. β -catenin signaling and cancer. *Bioessays* 21 (1999): 1021-1030.
 18. Shang S, F Hua, ZW Hu. The regulation of β -catenin activity and function in cancer: therapeutic opportunities. *Oncotarget* 8 (2017): 33972.
 19. Dalton S. Linking the cell cycle to cell fate decisions. *Trends in cell biology* 25 (2015): 592-600.
 20. Otto T, P Sicinski. Cell cycle proteins as promising targets in cancer therapy. *Nature Reviews Cancer* 17 (2017): 93-115.
 21. MacLachlan TK, N Sang, A Giordano. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. *Critical Reviews™ in Eukaryotic Gene Expression* 5 (1995).
 22. Mohammed MK, et al, Wnt/ β -catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. *Genes & diseases* 3 (2016): 11-40.
 23. Ewunkem AJ, et al. Diepoxybutane induces the p53-dependent transactivation of the CCL4 gene that mediates apoptosis in exposed human lymphoblasts. *Journal of Biochemical and Molecular Toxicology* (2023): e23316.
 24. Yadavilli S, PM Muganda. Diepoxybutane induces caspase and p53-mediated apoptosis in human lymphoblasts. *Toxicology and applied pharmacology* 195 (2004): 154-165.
 25. Yadavilli S, et al. Diepoxybutane activates the mitochondrial apoptotic pathway and mediates apoptosis in human lymphoblasts through oxidative stress. *Toxicology in Vitro* 21 (2007): 1429-1441.
 26. Stamos JL, Weis WI. The beta-catenin destruction complex. *Cold Spring Harbor Perspectives in Biology* 5 (2013): a007898.
 27. Dong J, et al. Induction of DNA damage and G2 cell cycle arrest by diepoxybutane through the activation of the Chk1-dependent pathway in mouse germ cells. *Chemical Research in Toxicology* 28 (2015): 518-531.
 28. Baek KH, J Choi, CZ Pei. Cellular functions of OCT-3/4 regulated by ubiquitination in proliferating cells. *Cancers* 12(2020): 663.
 29. Kim KP, et al. Biological importance of OCT transcription factors in reprogramming and development. *Experimental & Molecular Medicine* 53 (2021): 1018-1028.
 30. Anjos-Afonso F, D Bonnet. Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level? *Blood Journal* (2023): 2022018071.
 31. Su CY, et al. Analyzing the expression of biomarkers in prostate cancer cell lines. *In vivo* 35 (2021): 1545-1548.
 32. Fontana F, et al. Epithelial-to-mesenchymal transition markers and CD44 isoforms are differently expressed in 2D and 3D cell cultures of prostate cancer cells. *Cells* 8 (2019): 143.
 33. Fujiike AY, et al. Effects of docetaxel on metastatic prostate (DU-145) carcinoma cells cultured as 2D monolayers and 3D multicellular tumor spheroids. *Journal of Toxicology and Environmental Health, Part A* 87 (2024): 227-244.
 34. Geske F, et al. Early stages of p53-induced apoptosis are reversible. *Cell Death & Differentiation* 8 (2001): 182-191.
 35. Huang K, et al. Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. *Oncology letters* 8 (2014): 1441-1446.
 36. Le PM, et al. Cross-linking by epichlorohydrin and diepoxybutane correlates with cytotoxicity and leads to apoptosis in human leukemia (HL-60) cells. *Toxicology and Applied Pharmacology* 352 (2018): 19-27.
 37. Proposed Designation of 1,3-Butadiene (CASRN 106-99-0) as a High-Priority Substance for Risk Evaluation. United States Environmental Protection Agency. Office of Chemical Safety and Pollution Prevention (2019) Regulations.gov.
 38. Wilson T, P Johnston, D Longley. Anti-apoptotic mechanisms of drug resistance in cancer. *Current cancer drug targets* 9 (2009): 307-319.